Welcome to our dedicated page for Psyched Wellness news (Ticker: PSYCF), a resource for investors and traders seeking the latest updates and insights on Psyched Wellness stock.
Psyched Wellness Ltd. develops and distributes health and wellness products derived from the Amanita Muscaria mushroom. Company news centers on its consumer supplement portfolio, including Calm, Calmer, AME-1 extract and related dietary supplement formats, along with product formulation, shelf-life, safety-study and flavor-profile updates.
Recurring developments also include retail and wholesale distribution relationships in Canada and the United States, manufacturing and supply-chain matters, regulatory and policy commentary affecting botanical wellness products, and board or executive governance changes. The company’s updates often connect product commercialization with route-to-market partnerships and the regulatory risks associated with Amanita Muscaria-derived consumer products.
Psyched Wellness (PSYCF) has entered into secured term notes for an aggregate principal of US$244,541 with Gotham Green Fund I, L.P. and Gotham Green Fund I (Q), L.P.
The Loan will fund operating expenses and inventory purchases for the Company’s AMA-branded business. It bears interest at a rate equal to the applicable Secured Overnight Financing Rate (SOFR) plus 5% per annum, compounded annually, with principal and accrued interest due on September 9, 2028. Each Note is secured by a continuing security interest over all assets and property directly related to the AMA brand. The transaction is classified as a related party transaction under MI 61-101, and Psyched Wellness relies on exemptions from formal valuation and minority approval because the fair market value is below 25% of its market capitalization.
Psyched Wellness (OTCQB: PSYCF) has entered into secured term notes with Gotham Green Fund III, L.P. and Gotham Green Fund III (Q), L.P. for an aggregate principal of US$230,000. The Loan proceeds will fund operating expenses and inventory purchases for the Company’s AMA brand business.
The Loan bears interest at SOFR + 5% per annum, compounded annually, with principal and accrued interest payable on August 4, 2028. Each Note is secured by a continuing security interest over all assets and property directly related to the AMA brand. The transaction is a related party transaction under MI 61-101, and Psyched Wellness is relying on exemptions from formal valuation and minority approval because the fair market value does not exceed 25% of its market capitalization.
Psyched Wellness (CSE: PSYC, OTCQB: PSYCF) has launched a Board-led strategic review to evaluate options to enhance shareholder value, citing a belief that its current market valuation does not reflect commercial progress with Calm®, AME-1-based products, and its multi-brand ecosystem (Calm®, AMA, Santa).
The review will consider alternatives such as strategic partnerships, capital infusions, M&A, a go-private transaction, other strategic transactions, or maintaining an optimized growth plan. A Special Committee has been formed, there is no assurance of any transaction or outcome, and no defined completion timeline. Operations and commercial initiatives will continue during the process.
Psyched Wellness (OTCQB: PSYCF) announced several leadership changes. Jeff Stevens stepped down as Chief Executive Officer and resigned as a director effective May 31, 2026, and left all roles at subsidiary AME Wellness. Director Janeen Stodulski resigned June 9, 2026.
Effective June 1, 2026, Chairman Michael Nederhoff became Interim CEO while a permanent CEO search is conducted. The company states it remains focused on its strategic objectives and on delivering value to shareholders, customers, and other stakeholders.
Psyched Wellness (OTCQB: PSYCF) highlighted U.S. federal policy developments on April 23, 2026 that the company says could accelerate research, regulatory review, and potential rescheduling of psychedelic compounds. The company positions its Amanita muscaria–derived consumer products to benefit if federal actions broaden clinical pathways, access programs, and investor interest.
Psyched Wellness (OTCQB: PSYCF) launched Calmer, a 2x potency version of its flagship Calm dietary supplement derived from Amanita Muscaria, and rolled out an enhanced flavour profile for Calm in both 30 ml and 60 ml formats that reduces mushroom taste while keeping potency.
The launch coincides with a site-wide 40% Black Friday promotion (excluding merch) through December 1, 2025. Management says R&D concentrated AME-1 to increase potency without compromising experience. The company is expanding route-to-market partnerships across Canada and the United States and invites distributors to contact sales@psyched-wellness.com.
Psyched Wellness (OTCQB: PSYCF) provided an investor update on October 9, 2025 outlining product, scientific, patent and regulatory progress for its Amanita muscaria extract AME-1 and related products.
Key points: soft launch of dietary supplement shot Santa on Oct 1, 2025 after an initial production run and a second run planned for mid-October; a Genotoxicity study for AME-1 was initiated on Mar 14, 2025; an accelerated stability study supports an 18-month shelf life for Calm; a scaled-up extraction patent application was filed in the U.S. on Aug 18, 2025; a New Dietary Ingredient Notification was submitted to the FDA in July 2025 and FDA replied in September 2025 that the provided data did not demonstrate AME-1 would reasonably be expected to be safe.
Psyched Wellness (CSE: PSYC) (OTCQB: PSYCF) has completed an initial pilot run of a new 4 oz dietary supplement shot through its US subsidiary, AME Wellness Inc., in collaboration with Zerkalo
The pilot program aims to beta test the shot with select consumers to gather feedback on taste, effects, and marketing data. The company will also evaluate its website, third-party logistics, and shipping processes to ensure proper fulfillment capabilities before the product launch.
CEO Jeff Stevens expressed excitement about this development phase of the new dietary supplement shot, praising Zerkalo's brand development efforts. The company plans to expand its route-to-market partnerships nationwide for their product line.
Psyched Wellness (CSE: PSYC) (OTCQB: PSYCF), a life sciences company focused on Amanita Muscaria mushroom products, has announced key developments in their operations. The company will conduct a Genotoxicity Study on their proprietary Amanita Muscaria Extract (AME-1), following a comprehensive review of scientific data.
The company has successfully completed a production run for AME-1 and Calm products, ensuring sufficient inventory for online and retail orders. They are actively working to secure a long-term manufacturing agreement to meet growing demand.
Additionally, their consultant Zerkalo is making progress in developing new dietary supplement products using AME-1. The company has scheduled its Annual General and Special Meeting for May 15, 2025, and is expanding their route-to-market partnerships nationwide.
Psyched Wellness (CSE: PSYC) (OTCQB: PSYCF) announces changes to its board of directors. Harrison Aaron, a nominee of Gotham Green Partners, has resigned effective November 22, 2024. Trevor Mayer, Associate General Counsel at Gotham Green, has been appointed as the replacement nominee director. Mayer, who joined Gotham Green in 2019, brings experience in private equity M&A and fund formation from his previous roles at Kirkland & Ellis LLP and Cooley LLP. He graduated with honors from the University of Chicago Law School and the University of Texas at Austin.